Aquestive Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
AQST$3.61-1.4%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets as of March 31, 2024 and December 31, 2023
Condensed Balance Sheets
(In thousands, except share and per share amounts)
| March 31,2024 | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $95,200 | $23,872 |
| Trade and other receivables, net | 8,324 | 8,471 |
| Inventories | 7,734 | 6,769 |
| Prepaid expenses and other current assets | 2,121 | 1,854 |
| Total current assets | 113,379 | 40,966 |
| Property and equipment, net | 4,046 | 4,179 |
| Right-of-use assets, net | 5,442 | 5,557 |
| Intangible assets, net | 1,239 | 1,278 |
| Other non-current assets | 5,417 | 5,438 |
| Total assets | $129,523 | $57,418 |
| Liabilities and stockholders’ deficit | ||
| Current liabilities: | ||
| Accounts payable | $10,523 | $8,926 |
| Accrued expenses | 4,637 | 6,497 |
| Lease liabilities, current | 414 | 390 |
| Deferred revenue, current | 1,551 | 1,551 |
| Liability related to the sale of future revenue, current | 910 | 922 |
| Loans payable, current | 23 | 22 |
| Total current liabilities | 18,058 | 18,308 |
| Notes payable, net | 28,759 | 27,508 |
| Royalty obligations, net | 16,119 | 14,761 |
| Liability related to the sale of future revenue, net | 63,626 | 63,568 |
| Lease liabilities | 5,284 | 5,399 |
| Deferred revenue, net of current portion | 31,957 | 32,345 |
| Other non-current liabilities | 2,021 | 2,016 |
| Total liabilities | 165,824 | 163,905 |
| Contingencies (Note 19) | ||
| Stockholders’ deficit: | ||
| Common stock, $0.001 par value. Authorized 250,000,000 shares; 90,478,731 and 68,533,085 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 90 | 69 |
| Additional paid-in capital | 295,514 | 212,521 |
| Accumulated deficit | (331,905) | (319,077) |
| Total stockholders’ deficit | (36,301) | (106,487) |
| Total liabilities and stockholders’ deficit | $129,523 | $57,418 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.